Sharescart Research Club logo ×
Screener Research Unlisted Startup Funding New IPO New

  • Home
  • /
  • Kilpest India
Join Channel
Consolidated Standalone

3B Blackbio Dx

₹712 2.8 | 0.4%

Market Cap ₹535 Cr.

Stock P/E 21.1

P/B 2.5

Current Price ₹712

Book Value ₹ 287.4

Face Value 10

52W High ₹924

Dividend Yield 0.35%

52W Low ₹ 390

Edit Ratio

3B Blackbio Dx Research see more...

Overview Inc. Year: 1972Industry: Pesticides & Agrochemicals

Kilpest India Ltd is an totally agri-based business enterprise. The Company on the whole offers agrochemicals. The Company's agriculture business includes crop safety products and public health products, bio products, micro-vitamins and mix fertilizers. The Company gives chemical merchandise, which include pesticides, which include Bheem, Karfu, Frutofix, Kilzex D, Kildon, Pradhan and Shock; anti-bacterial products, along with Kiltomycin; fungicides, including Kiltaf, Micfun, Pearl, Ajomil and Blast; herbicides/weedicides, such as Stump, Chapet, Eraser and Baaz 50 E, and public health merchandise, inclusive of Kilvos76E, Bazooka, Lakshya and Kilothus. The Company gives organic merchandise, together with bio insecticides, along with Larvect 50, Mahakaal and Neemkil; bio fungicides, along with Suraksha; bio fertilizers (plant increase stimulants), inclusive of Sampada, Neemayu, Vardhak-G and Vardhak-90; bio nematicides; public health products, such as Roach Kill, Ann Rakshak and Repel-Mos, and health and hygiene products.

Read More..

3B Blackbio Dx Share Price

New

₹ | |

Volume
Price

Quarterly Price

Quarterly Monthly
Show Value Show %

Peer Comparison

3B Blackbio Dx Quarterly Results

#(Fig in Cr.) Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 15 14 18 12 17 15 18 14 19 18
Other Income 2 2 2 1 2 3 1 3 3 3
Total Income 17 16 20 13 19 18 19 17 22 20
Total Expenditure 9 7 12 7 8 7 11 8 11 9
Operating Profit 8 9 8 6 11 10 9 9 11 12
Interest 0 0 -0 0 0 0 0 0 0 0
Depreciation 0 0 0 0 0 0 0 0 0 0
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 8 8 8 6 11 10 8 9 10 11
Provision for Tax 2 2 3 2 3 2 3 2 3 3
Profit After Tax 6 7 5 5 8 8 5 7 8 9
Adjustments -1 -1 -1 -1 0 -1 -1 -1 0 0
Profit After Adjustments 5 6 4 4 8 7 5 6 8 9
Adjusted Earnings Per Share 6.8 7.7 5.5 5.4 9.8 7.9 6 8.4 9.2 10.2

3B Blackbio Dx Profit & Loss

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
Net Sales 20 22 19 17 16 23 23 29 227 81 62 69
Other Income 0 0 0 0 0 0 1 2 3 7 7 10
Total Income 20 22 19 17 16 23 24 30 230 88 69 78
Total Expenditure 19 21 18 16 14 18 16 20 77 44 33 39
Operating Profit 1 1 1 2 3 6 8 11 153 44 36 41
Interest 1 1 1 1 1 1 0 0 0 0 0 0
Depreciation 0 0 0 0 0 0 1 1 1 1 1 0
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 1 0 0 0 1 5 7 10 152 43 35 38
Provision for Tax 0 0 0 0 0 1 2 2 38 11 9 11
Profit After Tax 0 0 0 0 1 3 5 8 114 32 26 29
Adjustments 0 0 0 0 0 0 0 -0 0 0 0 -2
Profit After Adjustments 1 1 0 0 1 3 5 8 114 32 26 28
Adjusted Earnings Per Share 1.3 0.9 0.6 0.7 1.8 5.4 8.2 10.2 152 43 34.6 33.8

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR -23% 29% 22% 12%
Operating Profit CAGR -18% 48% 43% 43%
PAT CAGR -19% 48% 54% 0%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 63% 19% 54% 59%
ROE Average 16% 59% 47% 26%
ROCE Average 22% 77% 58% 32%

3B Blackbio Dx Balance Sheet

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Shareholder's Funds 10 10 10 10 11 18 23 32 132 153 171
Minority's Interest -0 -0 -0 -0 0 0 0 2 16 19 25
Borrowings 2 2 2 3 3 2 2 1 1 1 1
Other Non-Current Liabilities 1 1 1 1 1 1 1 1 1 2 3
Total Current Liabilities 11 11 12 10 11 9 10 8 43 17 14
Total Liabilities 23 24 25 24 26 30 36 45 194 192 214
Fixed Assets 4 4 4 3 3 4 4 4 5 7 8
Other Non-Current Assets 0 0 0 0 0 0 0 2 70 104 92
Total Current Assets 19 20 21 21 22 26 32 39 118 82 114
Total Assets 23 24 25 24 26 30 36 45 194 192 214

3B Blackbio Dx Cash Flow

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Opening Cash & Cash Equivalents 1 0 0 0 0 0 0 2 9 35 29
Cash Flow from Operating Activities -1 0 0 1 1 2 4 7 98 37 23
Cash Flow from Investing Activities 0 -0 -0 -0 -0 -1 -1 -1 -70 -28 12
Cash Flow from Financing Activities -0 0 -0 -1 -0 0 -1 1 -2 -15 -5
Net Cash Inflow / Outflow -1 0 -0 0 0 1 2 7 26 -6 30
Closing Cash & Cash Equivalent 0 0 0 0 0 2 2 9 35 29 59

3B Blackbio Dx Ratios

# Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Earnings Per Share (Rs) 1.32 0.94 0.56 0.69 1.77 5.37 8.2 10.25 152 42.98 34.62
CEPS(Rs) 0.97 0.98 0.82 1.16 2.48 6.08 9.06 10.98 152.82 43.88 35.77
DPS(Rs) 0 0 0 0 0.3 0.5 0.5 0.7 1 10.5 2.5
Book NAV/Share(Rs) 15.25 15.61 15.84 16.33 17.57 21.4 35.2 42.87 176.27 204.26 228.55
Core EBITDA Margin(%) 5.86 5.42 6.53 8 14.76 23.17 31.02 32.27 66.15 46 47.13
EBIT Margin(%) 5.43 4.7 5.53 6.46 13.71 22.4 31.85 35.97 67.15 53.73 57.42
Pre Tax Margin(%) 2.67 1.83 1.45 2.32 8.04 19.28 29.86 34.81 67.05 53.6 57.1
PAT Margin (%) 1.81 1.57 1.13 1.78 6.51 14.63 22.52 26.62 50.22 39.93 41.94
Cash Profit Margin (%) 2.77 2.6 2.56 3.94 9.12 16.58 24.87 28.48 50.49 40.76 43.34
ROA(%) 1.8 1.62 0.96 1.37 4.55 12.22 15.71 18.94 95.54 16.7 12.77
ROE(%) 4.31 3.86 2.33 3.26 10.47 27.55 28.99 28.15 138.73 22.59 16
ROCE(%) 7.96 6.97 6.6 6.8 12.52 23.8 28.04 32.29 179.46 29.92 21.6
Receivable days 185.24 188.48 233.78 261.7 290.63 239.28 274.14 242.8 44.04 146.56 188.65
Inventory Days 70.98 63.95 71.7 70.01 76.56 59.84 67.94 57.29 7.2 27.85 45.68
Payable days 186.08 156.1 192.18 188.74 0 113.29 124.67 100.56 22.43 37.45 70.42
PER(x) 6.2 7.99 14.62 11.45 19.45 24.9 9.21 7.08 1.87 7.94 12.01
Price/Book(x) 0.53 0.48 0.52 0.48 1.96 6.25 2.14 1.69 1.62 1.67 1.82
Dividend Yield(%) 0 0 0 0 0.87 0.37 0.66 0.96 0.35 3.08 0.6
EV/Net Sales(x) 0.55 0.52 0.66 0.71 1.87 3.86 2.19 1.68 0.79 2.84 4.11
EV/Core EBITDA(x) 7.74 8.16 8.68 7.61 10.69 15.7 6.41 4.44 1.18 5.21 6.99
Net Sales Growth(%) -4.93 8.38 -13.71 -8.4 -6.72 43.61 0.28 24.05 685.26 -64.43 -23.32
EBIT Growth(%) 24.74 -6.51 0.22 6.92 95.73 120.31 41.33 40.08 1366.08 -71.54 -18.05
PAT Growth(%) 3495.55 -6.01 -38.62 43.46 238.01 202.69 52.99 46.66 1381.27 -71.72 -19.45
EPS Growth(%) 148.49 -28.89 -39.67 22.2 157.19 202.57 52.81 24.95 1383.24 -71.72 -19.45
Debt/Equity(x) 0.62 0.69 0.74 0.74 0.78 0.42 0.28 0.11 0.02 0.02 0.01
Current Ratio(x) 1.67 1.8 1.81 1.98 2.05 3.03 3.08 4.82 2.76 4.82 8.05
Quick Ratio(x) 1.29 1.44 1.47 1.66 1.68 2.61 2.6 4.32 2.64 4.38 7.49
Interest Cover(x) 1.97 1.64 1.35 1.56 2.42 7.19 16.02 31.08 666.83 407.23 178.97
Total Debt/Mcap(x) 1.15 1.44 1.42 1.53 0.39 0.07 0.13 0.06 0.01 0.01 0.01

3B Blackbio Dx Shareholding Pattern

# Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
Promoter 38.43 38.43 38.43 38.43 38.43 38.43 38.43 38.43 38.43 41.29
FII 1.23 1.64 1.64 1.64 2.11 2.54 3.06 3.16 3.38 2.97
DII 0.08 0.08 0.08 0 0 0 0 0.82 1.18 1.89
Public 60.26 59.85 59.85 59.93 59.46 59.03 58.51 57.59 57 53.85
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Pros

  • Company has delivered good profit growth of 54% CAGR over last 5 years
  • Company has a good return on equity (ROE) track record: 3 Years ROE 59%
  • Company is almost debt free.

Cons

  • Promoter holding is low: 41.29%.
  • Debtor days have increased from 37.45 to 70.42days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

3B Blackbio Dx News

IPO

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

You May Also Know About

Unlisted Shares Pre-IPO Shares ESOP Shares Delisted Shares

Please Login!

Click to Login
OR
Get free Account

Error!